Associated tags: Therapy, Health, Pharmaceutical, Biotechnology, Clinical Trials, Patient, Pharmaceutical industry, Research, Incyte
Locations: FL, US, BRAZIL, SPAIN, CHINA, CRANBURY, NJ, CHICAGO, UNITED KINGDOM, IRELAND, BERLIN, ARIZONA, MONTREAL, QC, CA, ARGENTINA, MEXICO, LATIN AMERICA, COLOMBIA, POMPANO BEACH, CECIL, MOUNT SINAI, VERA, SAN FRANCISCO, CR, SHENZHEN, CN, UNITED STATES, NORTH AMERICA, NEVADA, DELAWARE
Biotechnology,
Other Health,
Health,
General Health,
Public Relations,
Investor Relations,
Pharmaceutical,
Oncology,
Communications,
Other Science,
Research,
Science,
PDT,
Bank,
Conference Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas.
Key Points:
- Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas.
- The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
Biotechnology,
General Health,
Other Health,
Health,
Pharmaceutical,
Goldman Sachs,
American Academy,
Hart–Scott–Rodino Antitrust Improvements Act,
B cell,
LLP,
Safety,
Skin,
Vital signs,
Centerview Partners,
Research,
ECG,
Covington & Burling,
MRGPRX2,
MRGPRX4,
Autoimmunity,
Therapy,
Science,
Escient,
Incidence,
Patient,
Acquisition,
Multimedia,
Atopic dermatitis,
CSU This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
Key Points:
- This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
- “These drug candidates are the result of the highly innovative research performed by Escient’s employees and scientific collaborators,” said Joshua A. Grass, President and Chief Executive Officer, Escient.
- Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction and Fenwick & West LLP acted as legal counsel for Escient.
- The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415.
If you are unable to participate, a replay of the conference call will be available for thirty days.
Key Points:
- If you are unable to participate, a replay of the conference call will be available for thirty days.
- The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415.
- To access the replay you will need the conference ID number 13745743.
- The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
Dermatology,
Vitiligo,
Prurigo nodularis,
Patient,
Collaboration,
Research,
Asthma,
JAK1,
HS,
Hidradenitis suppurativa,
PN,
CMS,
Autoimmunity,
Pharmaceutical industry Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
Key Points:
- Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
- CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
- “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Herve Hoppenot, Chief Executive Officer, Incyte.
- Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline ILUMETRI (tildrakizumab injection), original drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.”
The transaction is effective immediately upon the execution of the Collaboration and License Agreement.
Research,
Biotechnology,
Other Health,
Health,
Cosmetics,
Pharmaceutical,
Retail,
Science,
Oncology,
Dermatology,
Vitiligo,
Prurigo nodularis,
Patient,
Collaboration,
Asthma,
JAK1,
HS,
Hidradenitis suppurativa,
PN,
CMS,
Autoimmunity,
Pharmaceutical industry Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
Key Points:
- Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
- Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
- CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
- “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan.
Key Points:
- Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan.
- The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- Mr. Trotta received an award of 7,828 restricted stock units (RSUs) and an award of stock options to purchase 21,868 shares of the Company’s common stock, in each case with a grant and vesting commencement date of March 25, 2024.
- The stock options have an exercise price of $57.48 per share, which is equal to the closing price of the Company’s common stock on the grant date.
Biotechnology,
FDA,
Health,
Pharmaceutical,
Clinical Trials,
Prurigo nodularis,
Patient,
AAD,
JAK1,
Numerical,
American Academy,
Safety Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN).
Key Points:
- Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN).
- Median times to itch NRS4 were 58, 35 and 17 days for patients who received 15, 45 and 75 mg of povorcitinib, respectively, and was not estimable for the placebo arm.
- We are excited to be expanding research on povorcitinib into this new potential indication.”
The secondary endpoints of the study were also met.
- The most common treatment-emergent adverse events (TEAEs) among patients who received povorcitinib were headache (11.1%), fatigue (9.3%) and nasopharyngitis (7.4%).
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Patient,
AAD,
HS,
Abscess,
American Academy,
Safety Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% (Opzelura®) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS).
Key Points:
- Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% (Opzelura®) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS).
- Treatment-emergent adverse events (TEAEs) occurred in 38.2% of patients who applied ruxolitinib cream 1.5% versus 42.9% of patients who applied vehicle control.
- The most common TEAEs among patients receiving ruxolitinib cream 1.5% were COVID-19 (5.9%) and nasopharyngitis (5.9%).
- Discontinuation due to TEAEs were infrequent (ruxolitinib cream 1.5%, n=2 [5.9%]; vehicle control, n=0 [0%]), and no serious TEAEs were reported in the ruxolitinib cream 1.5% group.
Retrieved on:
Thursday, February 29, 2024
ANVISA,
DCR,
Knight Therapeutics,
TSX,
DLBCL,
GUD,
Therapy,
Health,
Non-Hodgkin lymphoma,
Patient,
ASCT,
Lenalidomide,
Knight,
Resolution MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.
Key Points:
- MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.
- Additionally, in October 2023, Knight received pricing approval for Minjuvi® from the Drugs Market Regulation Chamber (“CMED”).
- “In line with Knight’s commitment to advancing healthcare in Latin America, we are excited to launch Minjuvi in Brazil, an innovative treatment option for addressing a current unmet medical need,” said Samira Sakhia, Knight Therapeutics President and CEO.
- “Knight’s team in Brazil is thrilled to make Minjuvi® available to health care professionals and centers, improving DLBCL patient care in the country,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.
